The global Long-Acting Injectable (LAI) Antipsychotic market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Aripiprazole Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Long-Acting Injectable (LAI) Antipsychotic include Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada and Prolixin, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Injectable (LAI) Antipsychotic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Injectable (LAI) Antipsychotic. This report contains market size and forecasts of Long-Acting Injectable (LAI) Antipsychotic in global, including the following market information:
Global Long-Acting Injectable (LAI) Antipsychotic Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Long-Acting Injectable (LAI) Antipsychotic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Long-Acting Injectable (LAI) Antipsychotic Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Long-Acting Injectable (LAI) Antipsychotic Market Segment Percentages, by Type, 2023 (%)
Aripiprazole
Fluphenazine
Haloperidol
Others
Global Long-Acting Injectable (LAI) Antipsychotic Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Long-Acting Injectable (LAI) Antipsychotic Market Segment Percentages, by Application, 2023 (%)
Hospital
Retail Pharmacy
Others
Global Long-Acting Injectable (LAI) Antipsychotic Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Long-Acting Injectable (LAI) Antipsychotic Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Long-Acting Injectable (LAI) Antipsychotic revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Long-Acting Injectable (LAI) Antipsychotic revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
Outline of Major Chapters:
Chapter 1: Introduces the definition of Long-Acting Injectable (LAI) Antipsychotic, market overview.
Chapter 2: Global Long-Acting Injectable (LAI) Antipsychotic market size in revenue.
Chapter 3: Detailed analysis of Long-Acting Injectable (LAI) Antipsychotic company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-Acting Injectable (LAI) Antipsychotic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Long-Acting Injectable (LAI) Antipsychotic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long-Acting Injectable (LAI) Antipsychotic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long-Acting Injectable (LAI) Antipsychotic Overall Market Size
2.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size: 2023 VS 2030
2.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Long-Acting Injectable (LAI) Antipsychotic Players in Global Market
3.2 Top Global Long-Acting Injectable (LAI) Antipsychotic Companies Ranked by Revenue
3.3 Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Companies
3.4 Top 3 and Top 5 Long-Acting Injectable (LAI) Antipsychotic Companies in Global Market, by Revenue in 2023
3.5 Global Companies Long-Acting Injectable (LAI) Antipsychotic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long-Acting Injectable (LAI) Antipsychotic Players in Global Market
3.6.1 List of Global Tier 1 Long-Acting Injectable (LAI) Antipsychotic Companies
3.6.2 List of Global Tier 2 and Tier 3 Long-Acting Injectable (LAI) Antipsychotic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Market Size Markets, 2023 & 2030
4.1.2 Aripiprazole
4.1.3 Fluphenazine
4.1.4 Haloperidol
4.1.5 Others
4.2 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
4.2.1 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
4.2.2 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
4.2.3 By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Others
5.2 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
5.2.1 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
5.2.2 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
5.2.3 By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Market Size, 2023 & 2030
6.2 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue & Forecasts
6.2.1 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2024
6.2.2 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2025-2030
6.2.3 By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.3.2 US Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.3.3 Canada Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.3.4 Mexico Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.4.2 Germany Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.3 France Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.4 U.K. Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.5 Italy Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.6 Russia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.7 Nordic Countries Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.4.8 Benelux Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.5.2 China Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.3 Japan Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.4 South Korea Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.5 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.5.6 India Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.6.2 Brazil Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.6.3 Argentina Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030
6.7.2 Turkey Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.3 Israel Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.4 Saudi Arabia Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
6.7.5 UAE Long-Acting Injectable (LAI) Antipsychotic Market Size, 2019-2030
7 Long-Acting Injectable (LAI) Antipsychotic Companies Profiles
7.1 Alkermes
7.1.1 Alkermes Company Summary
7.1.2 Alkermes Business Overview
7.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.1.4 Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.1.5 Alkermes Key News & Latest Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Company Summary
7.2.2 Eli Lilly and Company Business Overview
7.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.2.4 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.2.5 Eli Lilly and Company Key News & Latest Developments
7.3 Janssen Global Services, LLC
7.3.1 Janssen Global Services, LLC Company Summary
7.3.2 Janssen Global Services, LLC Business Overview
7.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.3.4 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.3.5 Janssen Global Services, LLC Key News & Latest Developments
7.4 Abilify Maintena
7.4.1 Abilify Maintena Company Summary
7.4.2 Abilify Maintena Business Overview
7.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.4.4 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.4.5 Abilify Maintena Key News & Latest Developments
7.5 Haldol
7.5.1 Haldol Company Summary
7.5.2 Haldol Business Overview
7.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.5.4 Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.5.5 Haldol Key News & Latest Developments
7.6 Otsuka Pharmaceutical
7.6.1 Otsuka Pharmaceutical Company Summary
7.6.2 Otsuka Pharmaceutical Business Overview
7.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.6.4 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.6.5 Otsuka Pharmaceutical Key News & Latest Developments
7.7 Aristada
7.7.1 Aristada Company Summary
7.7.2 Aristada Business Overview
7.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.7.4 Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.7.5 Aristada Key News & Latest Developments
7.8 Prolixin
7.8.1 Prolixin Company Summary
7.8.2 Prolixin Business Overview
7.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Major Product Offerings
7.8.4 Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue in Global Market (2019-2024)
7.8.5 Prolixin Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Long-Acting Injectable (LAI) Antipsychotic Market Opportunities & Trends in Global Market
Table 2. Long-Acting Injectable (LAI) Antipsychotic Market Drivers in Global Market
Table 3. Long-Acting Injectable (LAI) Antipsychotic Market Restraints in Global Market
Table 4. Key Players of Long-Acting Injectable (LAI) Antipsychotic in Global Market
Table 5. Top Long-Acting Injectable (LAI) Antipsychotic Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Share by Companies, 2019-2024
Table 8. Global Companies Long-Acting Injectable (LAI) Antipsychotic Product Type
Table 9. List of Global Tier 1 Long-Acting Injectable (LAI) Antipsychotic Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Long-Acting Injectable (LAI) Antipsychotic Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Long-Acting Injectable (LAI) Antipsychotic Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Long-Acting Injectable (LAI) Antipsychotic Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Long-Acting Injectable (LAI) Antipsychotic Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Long-Acting Injectable (LAI) Antipsychotic Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2025-2030
Table 30. Alkermes Company Summary
Table 31. Alkermes Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 32. Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 33. Alkermes Key News & Latest Developments
Table 34. Eli Lilly and Company Company Summary
Table 35. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 36. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 37. Eli Lilly and Company Key News & Latest Developments
Table 38. Janssen Global Services, LLC Company Summary
Table 39. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 40. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 41. Janssen Global Services, LLC Key News & Latest Developments
Table 42. Abilify Maintena Company Summary
Table 43. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 44. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 45. Abilify Maintena Key News & Latest Developments
Table 46. Haldol Company Summary
Table 47. Haldol Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 48. Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 49. Haldol Key News & Latest Developments
Table 50. Otsuka Pharmaceutical Company Summary
Table 51. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 52. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 53. Otsuka Pharmaceutical Key News & Latest Developments
Table 54. Aristada Company Summary
Table 55. Aristada Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 56. Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 57. Aristada Key News & Latest Developments
Table 58. Prolixin Company Summary
Table 59. Prolixin Long-Acting Injectable (LAI) Antipsychotic Product Offerings
Table 60. Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue (US$, Mn) & (2019-2024)
Table 61. Prolixin Key News & Latest Developments
List of Figures
Figure 1. Long-Acting Injectable (LAI) Antipsychotic Segment by Type in 2023
Figure 2. Long-Acting Injectable (LAI) Antipsychotic Segment by Application in 2023
Figure 3. Global Long-Acting Injectable (LAI) Antipsychotic Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Long-Acting Injectable (LAI) Antipsychotic Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Long-Acting Injectable (LAI) Antipsychotic Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2023
Figure 8. By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 9. By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 10. By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 12. By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 14. By Region - Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 15. By Country - North America Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 16. US Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 20. Germany Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 21. France Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 28. China Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 32. India Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 34. Brazil Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share, 2019-2030
Figure 37. Turkey Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Long-Acting Injectable (LAI) Antipsychotic Revenue, (US$, Mn), 2019-2030
Figure 41. Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
